Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jul 2011 Planned end date changed from Feb 2010 to Feb 2012 as reported by ClinicalTrials.gov.